$OCGN this will get pushed back again. We’ll see $7’s later this week. And I honestly think we’ll see $5 before $20.
$OCGN Thiis is the latest on efficacy data. Safety and immunogencity data caame out in Phase-1 and Phase-2 trials "Unfortunately we have missed the efficacy time points, have done the Phase 2 and Phase 3 combined, we would have captured the efficacy faster," said Krishna Ella, Chairman and Managing Director of Bharat Biotech, speaking at BioAsia 2021. "Anyways we should be coming out in two week with efficacy data," Ella added.
View original message